Financhill
Sell
47

SRPT Quote, Financials, Valuation and Earnings

Last price:
$37.21
Seasonality move :
2.85%
Day range:
$37.88 - $39.56
52-week range:
$34.10 - $173.25
Dividend yield:
0%
P/E ratio:
20.50x
P/S ratio:
1.91x
P/B ratio:
3.30x
Volume:
4.2M
Avg. volume:
4.4M
1-year change:
-68.94%
Market cap:
$3.8B
Revenue:
$1.9B
EPS (TTM):
-$2.69

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
SRPT
Sarepta Therapeutics
$684.1M -$0.65 53.99% 1831.74% $89.96
ABBV
AbbVie
$12.9B $2.40 3.24% 313.38% $210.53
BMRN
Biomarin Pharmaceutical
$738.7M $0.95 7% 86.93% $95.91
EWTX
Edgewise Therapeutics
-- -$0.42 -- -23.95% $39.00
MRNA
Moderna
$115.3M -$3.11 -49.84% -11.55% $47.70
VRTX
Vertex Pharmaceuticals
$2.9B $4.29 9.83% 1.98% $502.98
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
SRPT
Sarepta Therapeutics
$38.35 $89.96 $3.8B 20.50x $0.00 0% 1.91x
ABBV
AbbVie
$185.72 $210.53 $328.1B 79.03x $1.64 3.44% 5.74x
BMRN
Biomarin Pharmaceutical
$58.11 $95.91 $11.1B 21.60x $0.00 0% 3.89x
EWTX
Edgewise Therapeutics
$14.33 $39.00 $1.5B -- $0.00 0% --
MRNA
Moderna
$26.76 $47.70 $10.3B -- $0.00 0% 3.32x
VRTX
Vertex Pharmaceuticals
$446.00 $502.98 $114.5B 26.10x $0.00 0% 10.41x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
SRPT
Sarepta Therapeutics
49.9% 3.156 18.15% 2.06x
ABBV
AbbVie
98.01% -0.326 18.88% 0.48x
BMRN
Biomarin Pharmaceutical
9.32% -0.133 4.39% 3.20x
EWTX
Edgewise Therapeutics
-- 1.971 -- --
MRNA
Moderna
-- 0.406 -- 3.92x
VRTX
Vertex Pharmaceuticals
-- 0.843 -- 2.12x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
SRPT
Sarepta Therapeutics
$607.3M -$300.4M -10.44% -20.94% -50.88% -$629.3M
ABBV
AbbVie
$9.3B $4B 5.54% 81.41% 17.7% $1.4B
BMRN
Biomarin Pharmaceutical
$593.6M $223.9M 8.4% 9.62% 32.34% $157.6M
EWTX
Edgewise Therapeutics
-- -$46M -- -- -- -$37.9M
MRNA
Moderna
$17M -$1.1B -29.23% -29.23% -900% -$1.2B
VRTX
Vertex Pharmaceuticals
$2.4B $1B -6.04% -6.04% 26.48% $778.2M

Sarepta Therapeutics vs. Competitors

  • Which has Higher Returns SRPT or ABBV?

    AbbVie has a net margin of -60.08% compared to Sarepta Therapeutics's net margin of 9.64%. Sarepta Therapeutics's return on equity of -20.94% beat AbbVie's return on equity of 81.41%.

    Company Gross Margin Earnings Per Share Invested Capital
    SRPT
    Sarepta Therapeutics
    81.53% -$4.60 $2.3B
    ABBV
    AbbVie
    70.01% $0.72 $71.4B
  • What do Analysts Say About SRPT or ABBV?

    Sarepta Therapeutics has a consensus price target of $89.96, signalling upside risk potential of 134.57%. On the other hand AbbVie has an analysts' consensus of $210.53 which suggests that it could grow by 13.36%. Given that Sarepta Therapeutics has higher upside potential than AbbVie, analysts believe Sarepta Therapeutics is more attractive than AbbVie.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRPT
    Sarepta Therapeutics
    14 5 0
    ABBV
    AbbVie
    12 12 0
  • Is SRPT or ABBV More Risky?

    Sarepta Therapeutics has a beta of 0.846, which suggesting that the stock is 15.365% less volatile than S&P 500. In comparison AbbVie has a beta of 0.557, suggesting its less volatile than the S&P 500 by 44.281%.

  • Which is a Better Dividend Stock SRPT or ABBV?

    Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AbbVie offers a yield of 3.44% to investors and pays a quarterly dividend of $1.64 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. AbbVie pays out 257.71% of its earnings as a dividend.

  • Which has Better Financial Ratios SRPT or ABBV?

    Sarepta Therapeutics quarterly revenues are $744.9M, which are smaller than AbbVie quarterly revenues of $13.3B. Sarepta Therapeutics's net income of -$447.5M is lower than AbbVie's net income of $1.3B. Notably, Sarepta Therapeutics's price-to-earnings ratio is 20.50x while AbbVie's PE ratio is 79.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 1.91x versus 5.74x for AbbVie. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRPT
    Sarepta Therapeutics
    1.91x 20.50x $744.9M -$447.5M
    ABBV
    AbbVie
    5.74x 79.03x $13.3B $1.3B
  • Which has Higher Returns SRPT or BMRN?

    Biomarin Pharmaceutical has a net margin of -60.08% compared to Sarepta Therapeutics's net margin of 24.92%. Sarepta Therapeutics's return on equity of -20.94% beat Biomarin Pharmaceutical's return on equity of 9.62%.

    Company Gross Margin Earnings Per Share Invested Capital
    SRPT
    Sarepta Therapeutics
    81.53% -$4.60 $2.3B
    BMRN
    Biomarin Pharmaceutical
    79.66% $0.95 $6.4B
  • What do Analysts Say About SRPT or BMRN?

    Sarepta Therapeutics has a consensus price target of $89.96, signalling upside risk potential of 134.57%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $95.91 which suggests that it could grow by 65.05%. Given that Sarepta Therapeutics has higher upside potential than Biomarin Pharmaceutical, analysts believe Sarepta Therapeutics is more attractive than Biomarin Pharmaceutical.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRPT
    Sarepta Therapeutics
    14 5 0
    BMRN
    Biomarin Pharmaceutical
    16 6 0
  • Is SRPT or BMRN More Risky?

    Sarepta Therapeutics has a beta of 0.846, which suggesting that the stock is 15.365% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.268, suggesting its less volatile than the S&P 500 by 73.157%.

  • Which is a Better Dividend Stock SRPT or BMRN?

    Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SRPT or BMRN?

    Sarepta Therapeutics quarterly revenues are $744.9M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.1M. Sarepta Therapeutics's net income of -$447.5M is lower than Biomarin Pharmaceutical's net income of $185.7M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 20.50x while Biomarin Pharmaceutical's PE ratio is 21.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 1.91x versus 3.89x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRPT
    Sarepta Therapeutics
    1.91x 20.50x $744.9M -$447.5M
    BMRN
    Biomarin Pharmaceutical
    3.89x 21.60x $745.1M $185.7M
  • Which has Higher Returns SRPT or EWTX?

    Edgewise Therapeutics has a net margin of -60.08% compared to Sarepta Therapeutics's net margin of --. Sarepta Therapeutics's return on equity of -20.94% beat Edgewise Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SRPT
    Sarepta Therapeutics
    81.53% -$4.60 $2.3B
    EWTX
    Edgewise Therapeutics
    -- -$0.43 --
  • What do Analysts Say About SRPT or EWTX?

    Sarepta Therapeutics has a consensus price target of $89.96, signalling upside risk potential of 134.57%. On the other hand Edgewise Therapeutics has an analysts' consensus of $39.00 which suggests that it could grow by 172.25%. Given that Edgewise Therapeutics has higher upside potential than Sarepta Therapeutics, analysts believe Edgewise Therapeutics is more attractive than Sarepta Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRPT
    Sarepta Therapeutics
    14 5 0
    EWTX
    Edgewise Therapeutics
    5 2 0
  • Is SRPT or EWTX More Risky?

    Sarepta Therapeutics has a beta of 0.846, which suggesting that the stock is 15.365% less volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock SRPT or EWTX?

    Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SRPT or EWTX?

    Sarepta Therapeutics quarterly revenues are $744.9M, which are larger than Edgewise Therapeutics quarterly revenues of --. Sarepta Therapeutics's net income of -$447.5M is lower than Edgewise Therapeutics's net income of -$40.8M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 20.50x while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 1.91x versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRPT
    Sarepta Therapeutics
    1.91x 20.50x $744.9M -$447.5M
    EWTX
    Edgewise Therapeutics
    -- -- -- -$40.8M
  • Which has Higher Returns SRPT or MRNA?

    Moderna has a net margin of -60.08% compared to Sarepta Therapeutics's net margin of -907.48%. Sarepta Therapeutics's return on equity of -20.94% beat Moderna's return on equity of -29.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    SRPT
    Sarepta Therapeutics
    81.53% -$4.60 $2.3B
    MRNA
    Moderna
    15.89% -$2.52 $10.1B
  • What do Analysts Say About SRPT or MRNA?

    Sarepta Therapeutics has a consensus price target of $89.96, signalling upside risk potential of 134.57%. On the other hand Moderna has an analysts' consensus of $47.70 which suggests that it could grow by 78.24%. Given that Sarepta Therapeutics has higher upside potential than Moderna, analysts believe Sarepta Therapeutics is more attractive than Moderna.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRPT
    Sarepta Therapeutics
    14 5 0
    MRNA
    Moderna
    5 17 1
  • Is SRPT or MRNA More Risky?

    Sarepta Therapeutics has a beta of 0.846, which suggesting that the stock is 15.365% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

  • Which is a Better Dividend Stock SRPT or MRNA?

    Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SRPT or MRNA?

    Sarepta Therapeutics quarterly revenues are $744.9M, which are larger than Moderna quarterly revenues of $107M. Sarepta Therapeutics's net income of -$447.5M is higher than Moderna's net income of -$971M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 20.50x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 1.91x versus 3.32x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRPT
    Sarepta Therapeutics
    1.91x 20.50x $744.9M -$447.5M
    MRNA
    Moderna
    3.32x -- $107M -$971M
  • Which has Higher Returns SRPT or VRTX?

    Vertex Pharmaceuticals has a net margin of -60.08% compared to Sarepta Therapeutics's net margin of 23.33%. Sarepta Therapeutics's return on equity of -20.94% beat Vertex Pharmaceuticals's return on equity of -6.04%.

    Company Gross Margin Earnings Per Share Invested Capital
    SRPT
    Sarepta Therapeutics
    81.53% -$4.60 $2.3B
    VRTX
    Vertex Pharmaceuticals
    86.9% $2.49 $16.5B
  • What do Analysts Say About SRPT or VRTX?

    Sarepta Therapeutics has a consensus price target of $89.96, signalling upside risk potential of 134.57%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $502.98 which suggests that it could grow by 12.14%. Given that Sarepta Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Sarepta Therapeutics is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRPT
    Sarepta Therapeutics
    14 5 0
    VRTX
    Vertex Pharmaceuticals
    14 13 1
  • Is SRPT or VRTX More Risky?

    Sarepta Therapeutics has a beta of 0.846, which suggesting that the stock is 15.365% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.511, suggesting its less volatile than the S&P 500 by 48.928%.

  • Which is a Better Dividend Stock SRPT or VRTX?

    Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SRPT or VRTX?

    Sarepta Therapeutics quarterly revenues are $744.9M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Sarepta Therapeutics's net income of -$447.5M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 20.50x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 1.91x versus 10.41x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRPT
    Sarepta Therapeutics
    1.91x 20.50x $744.9M -$447.5M
    VRTX
    Vertex Pharmaceuticals
    10.41x 26.10x $2.8B $646.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Apple Stock Undervalued or Overvalued?
Is Apple Stock Undervalued or Overvalued?

For many years, Apple (NASDAQ:AAPL) was just about the perfect…

Where Will Palo Alto Networks Stock Be in 5 Years?
Where Will Palo Alto Networks Stock Be in 5 Years?

You know those companies that just refuse to slow down…

UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?
UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?

Parcel delivery giant UPS (NYSE:UPS) has seen its fair share…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
58
TNXP alert for May 28

Tonix Pharmaceuticals Holding [TNXP] is up 1.57% over the past day.

Sell
37
ATS alert for May 28

ATS [ATS] is down 1.27% over the past day.

Buy
88
SMR alert for May 28

NuScale Power [SMR] is down 0.37% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock